Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ortho-McNeil-Janssen And Watson to Collaborate on CONCERTA Generic

By Pharmaceutical Processing | November 2, 2010

Ortho-McNeil-Janssen Pharmaceuticals, Inc. has entered into a supply and distribution agreement with
Watson Laboratories, Inc. to distribute an authorized generic version of
CONCERTA (methylphenidate HCl extended-release tablets). Watson will launch
the authorized generic beginning May 1, 2011.

“The availability of an authorized generic version of
CONCERTA that is both bioequivalent and clinically equivalent to the complex, extended-release
innovator compound is particularly important — and reassuring — for patients
with ADHD and their families,” states Don Heald, PhD, Vice President
Clinical Pharmacology, Neurosciences, Johnson & Johnson Pharmaceutical
Research & Development, L.L.C. “It is also important for healthcare
professionals who may consider prescribing a generic product for this
condition.” In 2004, the affiliate of OMJPI that marketed CONCERTA at that
time filed a Citizen Petition requesting generic versions of CONCERTA demonstrate
a similar onset of efficacy and a similar duration of effect to the innovator
product. The Citizen Petition, which remains under review by the Food and Drug
Administration (FDA), is not impacted by this agreement. McNeil Pediatrics, a
division of OMJPI, will continue to market the branded CONCERTA@ product.

Under the terms of the agreement, OMJPI will manufacture and
exclusively supply Watson with the authorized generic product, which will be
available in 18mg, 27mg, 36mg, and 54mg formulations. Watson will market and
distribute the product in the United
States until the end of 2014.

 

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE